SYRE Spyre Therapeutics Inc.

Price (delayed)

$79.05

Market cap

$6.86B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.12

Enterprise value

$6.77B

?
Relative Growth: Rel. Growth: 9
Relative Strength: Rel. Strength: 97
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 12

aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of ...

Highlights
The company's equity rose by 39% YoY but it fell by 6% QoQ
Spyre Therapeutics's quick ratio has decreased by 32% QoQ but it has increased by 9% YoY

Key stats

What are the main financial stats of SYRE

SYRE stock price

How has the Spyre Therapeutics stock price performed over time
Intraday
7.52%
1 week
9.62%
1 month
14.35%
1 year
378.51%
YTD
141.3%
QTD
56.72%

Financial performance

How have Spyre Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$201.64M
Net income
-$179.44M
Gross margin
N/A
Net margin
N/A
The net income has declined by 16% since the previous quarter but it has increased by 14% year-on-year
Spyre Therapeutics's operating income has increased by 6% YoY and by 3.8% QoQ

Price vs fundamentals

How does SYRE's price correlate with its fundamentals

Growth

What is Spyre Therapeutics's growth rate over time

Valuation

What is Spyre Therapeutics stock price valuation
P/E
N/A
P/B
9.26
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SYRE's EPS is up by 30% YoY but it is down by 7% QoQ
SYRE's P/B is 153% above its last 4 quarters average of 3.4
The company's equity rose by 39% YoY but it fell by 6% QoQ

Efficiency

How efficient is Spyre Therapeutics business performance
The company's return on equity rose by 36% YoY but it fell by 6% QoQ
SYRE's return on invested capital is up by 32% year-on-year but it is down by 8% since the previous quarter
Spyre Therapeutics's ROA has increased by 32% YoY but it has decreased by 7% from the previous quarter

Dividends

What is SYRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SYRE.

Financial health

How did Spyre Therapeutics financials performed over time
The company's total liabilities rose by 49% QoQ and by 7% YoY
Spyre Therapeutics's total assets has increased by 34% YoY
Spyre Therapeutics's debt is 100% lower than its equity
The company's equity rose by 39% YoY but it fell by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.